Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (231-240 of 280) with videos related to

Pageof 28
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|March 1, 2021
Stratification of Patients With Sjögren's Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic ImplicationsLucia Martin-Gutierrez, Junjie Peng, Nicolyn L Thompson, et al.
Lancet (London, England)|May 29, 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trialMegan E B Clowse, David A Isenberg, Joan T Merrill, et al.
Frontiers in Immunology|July 11, 2018
CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-αChristopher J M Piper, Meredyth G Ll Wilkinson, Claire T Deakin, et al.
Rheumatology (Oxford, England)|April 22, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Rheumatology (Oxford, England)|May 27, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Rheumatology (Oxford, England)|December 8, 2017
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Clinical and Experimental Rheumatology|February 25, 2026
Shared governance of international myositis networksTeerin Liewluck, Lisa G Rider, Karen Cheng, et al.
Arthritis and Rheumatism|August 29, 2013
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disordersFrederick W Miller, Robert G Cooper, Jiří Vencovský, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
RMD Open|August 6, 2016
Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokinesNadia Howard Tripp, Jessica Tarn, Andini Natasari, et al.
Pageof 28

Showing results (231-240 of 280) with videos related to

Sort By:
Pageof 28
Arthritis & Rheumatology (Hoboken, N.J.)|March 1, 2021
Stratification of Patients With Sjögren's Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic ImplicationsLucia Martin-Gutierrez, Junjie Peng, Nicolyn L Thompson, et al.
Lancet (London, England)|May 29, 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trialMegan E B Clowse, David A Isenberg, Joan T Merrill, et al.
Frontiers in Immunology|July 11, 2018
CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-αChristopher J M Piper, Meredyth G Ll Wilkinson, Claire T Deakin, et al.
Rheumatology (Oxford, England)|April 22, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Rheumatology (Oxford, England)|May 27, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Rheumatology (Oxford, England)|December 8, 2017
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Clinical and Experimental Rheumatology|February 25, 2026
Shared governance of international myositis networksTeerin Liewluck, Lisa G Rider, Karen Cheng, et al.
Arthritis and Rheumatism|August 29, 2013
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disordersFrederick W Miller, Robert G Cooper, Jiří Vencovský, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
RMD Open|August 6, 2016
Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokinesNadia Howard Tripp, Jessica Tarn, Andini Natasari, et al.
Pageof 28